Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration
Open Access
- 28 August 2025
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (9) , 4849-4854
Abstract
This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.Keywords
All Related Versions
Funding Information
- Democritus University of Thrace
This publication has 19 references indexed in Scilit:
- How do we manage hyperhemolysis syndromeTransfusion, 2024
- Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 TrialsKidney Medicine, 2024
- Eculizumab for management of hyperhemolysis syndrome in pediatric patients with sickle cell disease: A single‐center case seriesPediatric Blood & Cancer, 2024
- What is the role of complement in bystander hemolysis? Old concept, new insightsExpert Review of Hematology, 2024
- Challenges in the treatment and prevention of delayed hemolytic transfusion reactions with hyperhemolysis in sickle cell disease patientsTransfusion, 2019
- Successful Outcome of Hyperhemolysis in Sickle Cell Disease following Multiple Lines of Treatment: The Role of Complement InhibitionHemoglobin, 2018
- Immunological complications of blood transfusionsLa Presse Médicale, 2016
- Hyperhemolysis Syndrome without Underlying Hematologic DiseaseCase Reports in Hematology, 2015
- Haemolytic Transfusion Reactions2005
- Hyperhemolysis syndrome in anemia of chronic diseaseTransfusion, 2005